87
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The Correlation Between MYO9B Gene Polymorphism and Inflammatory Bowel Disease in the Guangxi Zhuang Population

, , , , , , , , , , & show all
Pages 9163-9172 | Published online: 01 Dec 2021

References

  • Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016;11:127–148. doi:10.1146/annurev-pathol-012615-044152
  • Hu S, Vich Vila A, Gacesa R, et al. Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD. Gut. 2021;70:285–296.
  • Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020;578:527–539. doi:10.1038/s41586-020-2025-2
  • Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434. doi:10.1038/nature06005
  • He W-Q, Wang J, Sheng J-Y, et al. Contributions of myosin light chain kinase to regulation of epithelial paracellular permeability and mucosal homeostasis. Int J Mol Sci. 2020;21(3):993. doi:10.3390/ijms21030993
  • Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut microbiota and intestinal trans-epithelial permeability. Int J Mol Sci. 2020;21(17):6402. doi:10.3390/ijms21176402
  • Schulzke JD, Bojarski C, Zeissig S, et al. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci. 2006;1072:288–299. doi:10.1196/annals.1326.027
  • Liping S, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136(2):551–563. doi:10.1053/j.gastro.2008.10.081
  • Sánchez de Medina F, Romero-Calvo I, Mascaraque C, Martínez-Augustin O. Intestinal inflammation and mucosal barrier function. Inflamm Bowel Dis. 2014;20(12):2394–2404. doi:10.1097/MIB.0000000000000204
  • Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol. 2017;35:119–147. doi:10.1146/annurev-immunol-051116-052424
  • Frenkel S, Bernstein CN, Sargent M, et al. Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease. PLoS One. 2019;14:e0217846. doi:10.1371/journal.pone.0217846
  • Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33–46. doi:10.1016/j.jcmgh.2017.03.007
  • Shigetomi K, Ikenouchi J. Regulation of the epithelial barrier by post- translational modifications of tight junction membrane proteins. J Biochem. 2018;163:265–272. doi:10.1093/jb/mvx077
  • Foerster E, Mukherjee T, Cabral-Fernandes L, et al. How autophagy controls the intestinal epithelial barrier. Autophagy. 2021:1–18. doi:10.1080/15548627.2021.1909406
  • Lu RY, Yang WX, Hu YJ. The role of epithelial tight junctions involved in pathogen infections. Mol Biol Rep. 2014;41:6591–6610. doi:10.1007/s11033-014-3543-5
  • Fries W, Belvedere A, Vetrano S. Sealing the broken barrier in IBD: intestinal permeability, epithelial cells and junctions. Curr Drug Targets. 2013;14(12):1460–1470. doi:10.2174/1389450111314120011
  • McGovern Dermot PB, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149(5):1163. doi:10.1053/j.gastro.2015.08.001
  • Wolters VM, Xu W, Zhao X, et al. Replication of genetic variation in the MYO9B gene in crohn’s disease. Hum Immunol. 2011;72(7):592–597. doi:10.1016/j.humimm.2011.03.025
  • Garg A, Zhao A, Erickson SL, et al. Pregnane X receptor activation attenuates inflammation-associated intestinal epithelial barrier dysfunction by inhibiting cytokine-induced myosin light-chain kinase expression and c-Jun N-terminal kinase 1/2 activation. J Pharmacol Exp Ther. 2016;359(1):91–101. doi:10.1124/jpet.116.234096
  • Hemkemeyer SA, Vollmer V, Schwarz V, et al. Local Myo9b RhoGAP activity regulates cell motility. J Biol Chem. 2021;296:100136. doi:10.1074/jbc.RA120.013623
  • Monsuur AJ, De Bakker PIW, Alizadeh BZ, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet. 2005;37(12):1341–1344. doi:10.1038/ng1680
  • Chandhoke SK, Mooseker MS. A role for myosin IXb, a motor-RhoGAP chimera, in epithelial wound healing and tight junction regulation. Mol Biol Cell. 2012;23:2468–2480. doi:10.1091/mbc.e11-09-0803
  • Hegan PS, Chandhoke SK, Barone C, et al. Mice lacking myosin IXb, an inflammatory bowel disease susceptibility gene, have impaired intestinal barrier function and superficial ulceration in the ileum. Cytoskeleton. 2016;73(4):163–179. doi:10.1002/cm.21292
  • Sanchez E, Alizadeh BZ, Valdigem G, et al. MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Hum Immunol. 2007;68:610–615. doi:10.1016/j.humimm.2007.03.006
  • Van Bodegraven AA, Curley CR, Hunt KA, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology. 2006;131(6):1768–1774. doi:10.1053/j.gastro.2006.09.011
  • Latiano A, Palmieri O, Valvano MR, et al. The association of MYO9B gene in Italian patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2008;27(3):241–248. doi:10.1111/j.1365-2036.2007.03551.x
  • Wang MJ, Xu XL, Yao GL, et al. MYO9B gene polymorphisms are associated with the risk of inflammatory bowel diseases. Oncotarget. 2016;7(37):58862–58875. doi:10.18632/oncotarget.11186
  • Hu J, Mei Q, Huang J, et al. Association of MYO9B gene polymorphisms with inflammatory bowel disease in Chinese Han population. World J Gastroenterol. 2014;20(23):7466–7472. doi:10.3748/wjg.v20.i23.7466
  • Torres J, Ellul P, Langhorst J, et al. European crohn’s and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019;13(6):673–85e. doi:10.1093/ecco-jcc/jjz051
  • Loy L, Roda G, Fiorino G, et al. Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Rev Gastroenterol Hepatol. 2019;13(6):547–555. doi:10.1080/17474124.2019.1605291
  • Powell JJ, Cook WB, Hutchinson C, et al. Dietary fortificant iron intake is negatively associated with the quality of life in patients with mildly active inflammatory bowel diseases. Nutr Metab. 2013;10:9. doi:10.1186/1743-7075-10-9
  • Queiroz NSF, Regueiro M. Safety considerations with biologics and new inflammatory bowel disease therapies. Curr Opin Gastroenterol. 2020;36:257–264. doi:10.1097/MOG.0000000000000607